Absstract of: US2022252597A1

A biosensor having a core/shell nanocomposite of TiO2/rGO formed by hydrothermally coating reduced graphene oxide (rGO) flakes on titanate nanowires.

Absstract of: AU2021208400A1

The present invention relates to a

Absstract of: US2022249645A1

The present invention relates to the modification of a live attenuated strain of Salmonella enterica serovar Typhi, wherein its natural surface-exposed polysaccharide and flagellin antigens may be converted to, or augmented by, those from other strains of Salmonella, including S. enterica serovars Paratyphi, Typhimurium and Enteritidis. The present invention also relates to modified strains of Salmonella enterica serovar Typhi being suitable for use as components of a vaccine for enteric fever and salmonellosis.

Absstract of: CN114854654A

本发明提供一种禽肠炎沙门氏菌活疫苗，包含有抗原和佐剂，其中抗原是活的肠炎沙门氏菌(Salmonella enterica)R073△aroA株，其保藏编号为CCTCC M 2022376。所述的肠炎沙门氏菌R073ΔaroA株是通过Red/ET同源重组系统把肠炎沙门氏菌R073株的aroA基因缺失制备的。本发明所提供的肠炎沙门氏菌疫苗可以通过传统的方法进行使用，比如通过经济易操作的喷雾和饮用水进行大规模的施用，也可以通过肌肉注射或其他的方式进行施用。

Absstract of: CN114854686A

本发明公开了特异性识别鼠伤寒沙门氏菌的T细胞亚群及其应用。具体地公开了特异性识别鼠伤寒沙门氏菌的CD4+TCRVβ6+T细胞亚群在制备用于治疗沙门氏菌病、筛选治疗沙门氏菌病的候选药物、制备用于增强机体抵抗和清除沙门氏菌感染的药物以及在抗鼠伤寒沙门氏菌的疫苗研究中的应用。本发明还提供了一种构建沙门氏菌病TCRβ链基因测序文库的方法。本发明首次发现了CD4+TCRVβ6+T细胞亚群具有特异性识别鼠伤寒沙门氏菌的功能，用鼠伤寒沙门氏菌感染小鼠后，CD4+TCRVβ6+T细胞亚群的频率显著升高，经实验表明CD4+TCRVβ6+T细胞亚群在抵抗和清除沙门氏菌感染的过程中具有重要作用。

Absstract of: US2022241395A1

Provided are surprisingly effective methods for inactivating pathogens, and for producing highly immunogenic vaccine compositions containing an inactivated pathogen rendered noninfectious by exposure to a Fenton reagent, or by exposure to a Fenton reagent or a component thereof in combination with a methisazone reagent selected from the group consisting of methisazone, methisazone analogs, functional group(s)/substructure(s) of methisazone, and combinations thereof. The methods efficiently inactivate pathogens, while substantially retaining pathogen antigenicity and/or immunogenicity, and are suitable for inactivating pathogens, or for the preparation of vaccines for a wide variety of pathogens with genomes comprising RNA or DNA, including viruses and bacteria. Also provided are highly immunogenic inactivated vaccine compositions prepared by using any of the disclosed methods, and methods for eliciting an immune response in a subject by administering such vaccine compositions.

Absstract of: WO2022162303A1

It is essential to have efficient, simple, quick and transportable tools for reliably identifying bacteria that are multiresistant to antibiotics, more specifically broad-spectrum beta-lactamase (BSBL)-producing Enterobacteriaceae, which are the most widespread among Enterobacteriaceae. The present invention meets this requirement through its ease of use and its speed. The invention is based on detecting the enzyme activity of beta-lactam hydrolysis using an antibody capable of discriminating between the intact form of the beta-lactam ring of a beta-lactam and its hydrolysis product. This antibody can be used in kits and methods enabling for rapidly detecting (in less than one hour), without using expensive equipment (a small strip visible to the naked eye), the presence of bacteria producing penicillin-type, plasmid-mediated or hyper-produced AmpC enzymes, of BSBL or carbapenemase from colonies or in a sample.

Absstract of: GB2603362A

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

Absstract of: US2022233681A1

Disclosed herein are transgenic Salmonella typhi Ty21a comprising a chromosome with one or more heterologous nucleic acid regions, wherein the heterologous nucleic acid regions encode one or more viral antigens and are integrated into the Salmonella typhi Ty21a chromosome, and wherein the transgenic Salmonella typhi Ty21a stably expresses the one or more viral antigens. Also disclosed herein are compositions and vaccines comprising the transgenic Salmonella typhi Ty21a. Also disclosed herein are methods of eliciting an immune response in a subject against a SARS-CoV-2 viral antigen and/or a Salmonella typhi antigen comprising administering one or more doses of the composition or the vaccine to the subject. Also disclosed herein are methods of treating, preventing or reducing the incidence of COVID-19 and/or typhoid fever in a subject comprising administering one or more doses of the composition or the vaccine to the subject.

Absstract of: US2022233673A1

A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

Absstract of: US2022235098A1

The present disclosure discloses a Microcin MccY, and a preparation method and use thereof, wherein the amino acid sequence of the Microcin MccY is GGRGHIAEYFSGPITQVSFYG. Compared with Microcin MccJ25 that only has a bactericidal activity against a small part of serotypes of Salmonella such as Salmonella enteritidis, the Microcin MccY has bacteriostatic/bactericidal effects on Salmonella Pullorum, Salmonella typhimurium, Salmonella kentucky, Salmonella Infantis, Salmonella London, and Shigella sonnei, and can kill other serotypes of Salmonella that MccJ25 cannot kill. Especially, the Microcin MccY has an outstanding bactericidal effect on Salmonella typhimurium and Salmonella Pullorum which are common in livestock and poultry production, and meanwhile it also has bacteriostatic/bactericidal effects on Shigella sonnei. Therefore, the Microcin MccY overcomes the shortcoming of the narrow spectrum of the Microcin, has breakthrough significance, and has the potential as a substitute to antibiotics.

Absstract of: WO2022156055A1

Provided is the microcin MccY, wherein the amino acid sequence of the microcin is GGRGHIAEYFSGPITQVAFYG. Further provided are a method for preparing the microcin and the use thereof. Compared with MccJ25 which only has bactericidal activity on a small part of serotype salmonella such as enteritis, the small rhizomorph MccY has a bacteriostatic/bactericidal effect on Salmonella pullorum, Salmonella typhimurium, Salmonella kentucky, Salmonella infantis, Salmonella London and Shigella sonnei, and can kill other salmonella serotypes which cannot be killed by MccJ25; in particular, the small rhizomorph MccY has a remarkable bactericidal effect on Salmonella typhimurium and Salmonella pullorum which are common in livestock and poultry production, also has a bacteriostatic/bactericidal effect on Shigella sonnei, thereby overcoming the shortcoming of the small rhizomorph having a narrow spectrum.

Absstract of: AU2015261905A1

The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of heterologous proteins into eukaryotic cells.

Absstract of: WO2020229846A2

Pharmaceutical compositions and preparation including outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides.

Absstract of: EP3808372A1

A Shigella flexneri O-antigen of a first serotype or subserotype for use in raising an immune response against one or more Shigella flexneri O-antigen of a different serotype or subserotype, together with associated binding moieties, pharmaceutical compositions, kits, uses or methods.

Absstract of: US2022226396A1

The invention relates to means for carrying out conjugation between bacteria, and in particular the invention relates to carrier bacteria comprising antimicrobial agents and methods of use. The carrier bacteria are capable of conjugative transfer of DNA encoding the agent to a target cells. The invention further relates to growth or feed conversion ratio promotion in animals. The invention further relates to killing Salmonella or inhibiting the growth or proliferation of Salmonella.

Absstract of: US2022227846A1

The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.

Absstract of: US2022218810A1

The present invention relates to an immunogenic composition for Proteobacteria protection and reduced transmission. We have identified Proteobacteria serovar variant combinations that generate an immune response capable of robustly driving bacterial enteropathogens into an evolutionary dead end and reducing the transmission of the bacterium. These inactivated immunogenic positions and typically oral vaccines are easy to apply, cheap to produce, and can be stored long-term without cold-chain requirements making them ideal for application in livestock, or in resource-poor areas. They are believed to be the only immunogenic compositions and vaccine formulations capable of breaking the chain of transmission for these types of pathogen.

Absstract of: WO2021044436A2

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

Absstract of: CN114732898A

本发明涉疫苗领域，具体而言涉及一种CpG佐剂与抗原的定点共价结合方法。本发明方法基于分步偶联策略，通过在SpyTag序列的N端或C端添加单个半胱氨酸，使其能够与马来酰亚胺修饰的CpG佐剂偶联，并利用液相色谱技术纯化制备CpG‑SpyTag；将抗原N端或C端与SpyCatcher融合表达并纯化；将融合表达的抗原与CpG‑SpyTag体外连接，获得抗原与CpG佐剂1:1摩尔比的偶联产物。根据本发明技术方面制备的偶联产物提高了疫苗免疫效果，降低了佐剂使用量。

Absstract of: WO2021044436A2

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

Absstract of: WO2021099982A1

The present invention provides a glycoconjugate for administration to a subject in a method comprising the steps of: (i) administering a first dose of glycoconjugate; (ii) subsequently administering a second dose of glycoconjugate; wherein the amount of glycoconjugate in the first dose or first and second doses are atypically low, and also related aspects.

Absstract of: WO2022141937A1

Provided in the present invention is a specific molecular target for detecting five Salmonella strains. The molecular target is: (a) any one or several nucleotide sequences as shown in SEQ ID NOs: 1-5; or (b) a nucleotide sequence obtained by substituting, deleting or adding of one or several nucleotides of the nucleotide sequence in (a) and having at least 90% homology thereto. Further provided in the present invention are five Salmonella standard strains containing the specific molecular target, which respectively have deposit numbers of GDMCC 60847, GDMCC 60848, GDMCC 60849 and GDMCC 60850.

Absstract of: WO2021041822A1

The present invention relates, in part, to compositions and methods for enhancement of an immune response and for increased vaccine efficacy by stimulation of the TLR5 receptor, for example, with a recombinant TLR5 agonist (e.g., a flagellin-based agent or variant thereof).

Absstract of: WO2021125982A1

Attenuated, non-pathogenic strain of Salmonella enteritidis 3934Vac DwaaL of rough phenotype, modified to express the xenoantigen of the capsid protein (CAP) of porcine circovirus type 2 (PCV-2), and the method for obtaining said modified strain of Salmonella enteritidis. Also disclosed is a recombinant, effective and innocuous live anti-PCV-2 vaccine for pigs, developed using a process comprising the insertion and integration of the xenoantigen of the CAP of PCV-2 into the chromosome or plasmid of the attenuated, non-pathogenic strain of Salmonella enteritidis 3934Vac DwaaL.